1st Quarter - Report

CYSTIC FIBROSIS FOUNDATION for CYSTIC FIBROSIS FOUNDATION

Firm
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

House, Senate, FDA on EXPERRT Act (HR 4156, S 2218), Energy and Commerce and Labor-HHS Committee on Prescription Drug User Fee Act Agreement (PDUFA V), funding for National Center for Advancing Translational Sciences (NCATS) at NIH, FDA funding, NIH funding, Appropriations testimony, FTC on MedCo ExpressScripts merger, CMS on Medicare and Medicaid, Congressional CF Caucus, HHS comments on health reform and other regulations, FDA on Kalydeco

LobbyistCovered position, as disclosed
ERIC CHAMBERLAIN —
MARY B DWIGHT Legislative Correspondent; Legislative Assistant
JACQUELINE ERDO —
STEPHANIE KRENRICH Sr. Leg. Asst.; Leg. Asst.; Leg. Aide; Leg. Corr.
JASON RANVILLE —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); SENATE; Social Security Administration (SSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH)

Bills named: H.R. 4156 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.